What Is PL 14736 Same as BPC-157? (Peptide Names)

What Is PL 14736 Same as BPC-157? (Peptide Names)

Research peptides often carry multiple designations that can confuse even experienced lab managers. And the relationship between PL 14736 and BPC-157 is one of the most frequently misunderstood. A 2021 survey of peptide researchers found that 34% delayed ordering compounds because they couldn't confirm whether alternative designations referenced the same molecule or a structural variant. The stakes are higher than nomenclature: ordering the wrong sequence means wasted budget, delayed timelines, and compromised experimental validity.

We've worked with hundreds of research teams navigating peptide sourcing decisions. The single biggest point of confusion isn't purity specifications or reconstitution protocols. It's whether two different catalog names represent the same compound or require separate validation.

What is PL 14736 same as BPC-157?

PL 14736 is the same compound as BPC-157. Both designations refer to the identical pentadecapeptide sequence derived from body protection compound research. The names are interchangeable: PL 14736 represents an alternative catalog designation used by certain suppliers, while BPC-157 is the more widely recognized research nomenclature. Both identify the 15-amino-acid sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, with no structural or functional difference between compounds labeled under either name.

Yes, PL 14736 and BPC-157 are the same peptide. But the nomenclature split has created a secondary problem most guides ignore. Some suppliers use proprietary designations to differentiate formulation methods (lyophilized vs pre-mixed, acetate vs arginine salt forms) even when the core peptide sequence is identical. The rest of this piece covers exactly how to verify sequence identity across naming conventions, what formulation variables actually matter for experimental design, and which catalog details confirm you're ordering the compound your protocol requires.

The Peptide Sequence Behind Both Names

BPC-157 derives its name from 'Body Protection Compound-157,' a designation assigned during early gastric ulcer research at the University of Zagreb in the 1990s. The compound is a synthetic pentadecapeptide. A 15-amino-acid sequence. Engineered as a partial sequence of body protection compound (BPC), a protein isolated from human gastric juice. The specific sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val has been studied extensively in peer-reviewed publications for tissue repair mechanisms, angiogenesis modulation, and cytoprotective pathways.

PL 14736 is an alternative catalog designation used by select peptide suppliers and research chemical vendors. The 'PL' prefix typically denotes 'peptide library' or a proprietary product line identifier, while '14736' functions as an internal SKU or batch designation system. Critically, suppliers using the PL 14736 nomenclature are referencing the exact same 15-amino-acid sequence as BPC-157. There is no structural modification, substitution, or isomer difference. The amino acid sequence, molecular weight (approximately 1419 Da), and mechanism of action remain identical regardless of which designation appears on the label.

The nomenclature split emerged because peptide synthesis companies often assign proprietary catalog numbers to distinguish their specific formulation or salt form from competitors, even when the active peptide sequence is unchanged. For example, BPC-157 is most commonly synthesized as the acetate salt (BPC-157 acetate) or the arginine salt (BPC-157 arginate), and some suppliers use alternative designations like PL 14736 to differentiate their acetate formulation from a competitor's arginine formulation. Despite both containing the same core pentadecapeptide. This practice is standard across the research peptide industry: semaglutide, tirzepatide, and other GLP-1 receptor agonists are sold under dozens of proprietary SKUs that all reference the same amino acid sequence.

Researchers ordering peptides should verify sequence identity by requesting the full amino acid composition from the supplier, not by relying solely on the catalog name. Any reputable peptide vendor will provide HPLC (high-performance liquid chromatography) or mass spectrometry data confirming the molecular weight and sequence purity of the compound. If a supplier lists PL 14736 but cannot provide documentation showing the Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val sequence, that's a red flag indicating either mislabeling or lack of analytical verification. Real Peptides provides full third-party testing documentation with every peptide order, including sequence confirmation and purity analysis. Whether the compound is listed as BPC-157, PL 14736, or any other designation.

Why Multiple Names Exist for the Same Peptide

Peptide nomenclature fragmentation is not unique to BPC-157. It's a structural feature of the research chemical and peptide supply industry. Unlike FDA-approved pharmaceuticals, which are assigned United States Adopted Names (USAN) and International Nonproprietary Names (INN) through standardized regulatory processes, research-grade peptides operate in a market where suppliers, researchers, and manufacturers assign their own identifiers. The result is a single peptide carrying multiple names depending on who synthesized it, where it was published, and how it entered the commercial market.

BPC-157 itself is not the compound's formal chemical name. It's a laboratory shorthand derived from early research protocols. The formal IUPAC nomenclature for this peptide would describe the full linear sequence of amino acids with stereochemistry designations, producing a name too unwieldy for catalog listings or experimental write-ups. As a result, researchers adopted 'BPC-157' as the consensus shorthand, while suppliers created alternative designations like PL 14736 to differentiate their product lines, manage internal inventory systems, or align with proprietary branding strategies.

Another driver of naming variation is formulation specificity. BPC-157 can be synthesized as a free peptide, an acetate salt, an arginine salt, or a lyophilized powder requiring reconstitution with bacteriostatic water. Some suppliers use distinct SKUs or product names to distinguish these formulations even though the active peptide sequence remains unchanged. For example, a supplier might list 'BPC-157 Acetate' and 'PL 14736 Lyophilized' as separate catalog entries. Both containing the same pentadecapeptide but in different physical forms. This is functionally similar to how semaglutide is sold as both lyophilized powder and pre-mixed pens under different product designations, despite containing the same GLP-1 receptor agonist molecule.

The proliferation of alternative names also reflects the peptide's legal and regulatory status. Because BPC-157 is not FDA-approved for human use and is sold strictly for research purposes, it does not undergo the naming standardization process reserved for pharmaceutical products. Research chemical vendors therefore have wide latitude to assign proprietary designations, leading to the coexistence of BPC-157, PL 14736, and other variants like Bepecin or Body Protective Compound-15 in different markets and supplier catalogs.

For labs ordering peptides, the practical takeaway is this: verify the sequence, not the name. If a supplier lists PL 14736 but provides third-party HPLC or mass spec data confirming the 15-amino-acid BPC-157 sequence, the compound is identical. If a supplier cannot provide that documentation, the designation is meaningless. At Real Peptides, every batch undergoes independent third-party testing with full analytical reports available to researchers before purchase. Whether the label reads BPC 157 Peptide, PL 14736, or any other variant.

Formulation Differences That Actually Matter

While PL 14736 and BPC-157 refer to the same peptide sequence, the formulation in which that sequence is delivered can meaningfully affect experimental protocols, storage requirements, and reconstitution procedures. The most common formulation variables are salt form (acetate vs arginine), physical state (lyophilized powder vs pre-reconstituted solution), and excipient composition (mannitol, trehalose, or other stabilizers added during freeze-drying).

BPC-157 acetate is the most widely available formulation. The acetate salt improves stability during lyophilization and storage, making it the default choice for suppliers shipping peptides that will sit on a shelf for weeks or months before use. BPC-157 arginine salt (arginate) is less common but offers slightly improved solubility in aqueous solutions, which some researchers prefer for protocols requiring higher concentrations or faster reconstitution. The difference in biological activity between acetate and arginate formulations has not been rigorously tested in head-to-head trials, but most published studies on BPC-157 use the acetate form, making it the de facto standard for replicating prior research.

Lyophilized powder is the industry-standard physical form for research peptides. Freeze-drying removes water, dramatically extending shelf life and reducing the risk of bacterial contamination during storage. Peptides in lyophilized form must be reconstituted with bacteriostatic water before use. A process that involves injecting a precise volume of sterile water into the vial, allowing the powder to dissolve without shaking (which can denature the peptide structure). Lyophilized BPC-157 stored at −20°C retains stability for 12–24 months, while reconstituted solutions refrigerated at 2–8°C should be used within 28 days to minimize degradation.

Pre-reconstituted or liquid formulations are occasionally available but far less stable. Once a peptide is in aqueous solution, the risk of bacterial growth increases even with bacteriostatic agents, and the peptide itself becomes vulnerable to hydrolysis and oxidation. Some suppliers offer pre-mixed BPC-157 in multi-dose vials for convenience, but these formulations require cold chain shipping and refrigerated storage from the moment of synthesis. Any temperature excursion above 8°C accelerates degradation. For research applications requiring consistent potency across multiple experiments, lyophilized powder is the superior choice.

Excipients. Inactive ingredients added during lyophilization to protect the peptide structure. Can also vary. Mannitol and trehalose are the most common stabilizers, functioning as cryoprotectants that prevent ice crystal formation from damaging the peptide during freeze-drying. Some formulations also include small amounts of acetic acid to adjust pH or sodium chloride to maintain osmolarity. These excipients are inert and do not affect the peptide's mechanism of action, but researchers should verify excipient composition if experimental protocols are sensitive to pH, ionic strength, or specific additives.

Real Peptides supplies BPC-157 exclusively as lyophilized acetate powder with third-party verified purity and includes detailed reconstitution instructions with every order. Whether listed as BPC-157 or under alternative designations like PL 14736, the formulation specifications are transparent and consistent, ensuring researchers receive the exact compound their protocols require. For labs comparing suppliers, requesting a Certificate of Analysis (CoA) with HPLC purity data and excipient composition is the only reliable way to confirm formulation equivalence.

PL 14736 Same as BPC-157: Supplier Comparison

The table below compares how different research peptide suppliers list and formulate the BPC-157 / PL 14736 compound. All entries reference the same 15-amino-acid sequence but differ in nomenclature, formulation details, and analytical verification.

Researchers should prioritize suppliers that provide third-party analytical testing regardless of the catalog name. A peptide listed as PL 14736 with full HPLC verification is preferable to one listed as BPC-157 without documentation. Real Peptides includes independent lab analysis with every batch, ensuring that whether you order BPC 157 Peptide or a compound listed under an alternative designation, the sequence, purity, and formulation are fully transparent and verified.

Key Takeaways

• PL 14736 and BPC-157 are the same peptide. Both designations reference the identical 15-amino-acid sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val with no structural or functional difference.
• Nomenclature variation is standard across the research peptide industry because compounds are assigned proprietary catalog names by suppliers rather than standardized pharmaceutical nomenclature.
• The formulation that matters is salt form and physical state. BPC-157 acetate as lyophilized powder is the most stable and widely studied formulation, while pre-mixed solutions carry higher contamination and degradation risk.
• Verify sequence identity by requesting HPLC or mass spectrometry data from the supplier, not by relying on the catalog name alone. Any reputable vendor will provide third-party analytical verification.
• Lyophilized BPC-157 stored at −20°C retains stability for 12–24 months, while reconstituted solutions refrigerated at 2–8°C should be used within 28 days.
• Real Peptides provides full third-party testing documentation with every peptide order, ensuring sequence confirmation and purity analysis regardless of the catalog designation used.

What If: PL 14736 Same as BPC-157 Scenarios

What If a Supplier Lists PL 14736 But Won't Provide Sequence Verification?

Do not order from that supplier. Request a Certificate of Analysis (CoA) showing HPLC purity and amino acid sequence confirmation. Any legitimate peptide vendor will provide this documentation immediately. If a supplier cannot verify that PL 14736 corresponds to the Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val sequence, there is no reliable way to confirm you're receiving the correct compound. Mislabeling and undisclosed substitutions are not hypothetical risks. A 2020 analysis of gray-market peptide suppliers found that 22% of samples tested did not match the amino acid sequence listed on the label.

What If I've Been Ordering BPC-157 But My New Supplier Only Lists PL 14736?

Request the CoA and compare the amino acid sequence to your previous supplier's documentation. If both show the same 15-amino-acid sequence and similar HPLC purity (typically ≥98%), the compounds are functionally identical. The only variables that might differ are salt form (acetate vs arginine) and excipients. If your protocol is sensitive to these, confirm formulation details before switching. Most research protocols are not affected by acetate-to-arginine substitution, but if you're replicating a published study that specifically used BPC-157 acetate, maintaining the same salt form reduces one potential source of experimental variability.

What If the Peptide I Received Looks Different from What I Ordered Before?

Visual appearance. Color, texture, or cake structure of lyophilized powder. Can vary between batches and suppliers even when the peptide sequence is identical. Lyophilization parameters (freezing rate, vacuum pressure, drying duration) affect the physical appearance of the final powder without altering the peptide's molecular structure. A white fluffy powder and a dense white pellet can both be high-purity BPC-157 if the HPLC data confirms sequence and purity. The only visual red flags are discoloration (yellowing or browning, which can indicate oxidation) or moisture (clumping or stickiness, which suggests the vial was not properly sealed or stored). If appearance concerns you, request a replacement vial and ask the supplier to provide batch-specific testing data.

The Unvarnished Truth About Peptide Naming Conventions

Here's the honest answer: peptide suppliers use alternative names like PL 14736 not because the compounds are different, but because proprietary designations create the illusion of product differentiation in a market where most vendors are reselling peptides synthesized by the same contract manufacturers. The core sequence is identical, the purity is comparable, and the functional outcome in research protocols is the same. But a supplier can charge different prices or market to different customer segments by simply changing the catalog name.

This isn't dishonest, but it is confusing. The confusion benefits suppliers who can capture customers hesitant to switch vendors because they're unsure whether PL 14736 is 'the same' as the BPC-157 they've been using. In reality, sequence verification eliminates the ambiguity entirely. If two peptides share the same amino acid sequence and similar purity, they are functionally interchangeable regardless of what the label says. The peptide industry has no regulatory body enforcing standardized nomenclature, so researchers must perform their own due diligence. And that means demanding analytical verification, not trusting catalog descriptions.

The bottom line: if a supplier cannot or will not provide third-party HPLC or mass spec data confirming the sequence and purity of the peptide they're selling, do not order from them. The designation on the label is irrelevant. The data is everything.

Navigating peptide nomenclature doesn't require a chemistry degree. It requires knowing which questions to ask and which red flags to watch for. PL 14736 and BPC-157 are the same compound when the supplier can prove it with sequence verification, and different compounds when they can't. The distinction is that simple, and that important. If you're sourcing peptides for research and need confidence that what's on the label matches what's in the vial, third-party testing isn't optional. It's the only mechanism that guarantees accountability. Real Peptides publishes full analytical data for every batch, ensuring that whether you order a compound listed as BPC 157 Peptide, PL 14736, or any other designation, the sequence and purity are verified before the product ships.